Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This study evaluates the efficacy, safety and pharmacokinetics of tinostamustine (EDO-S101)
in patients with relapsed/refractory hematologic malignancies. All patients will receive
tinostamustine.